EYPT EyePoint Pharmaceuticals Inc.

1.69
-0.09  -5%
Previous Close 1.78
Open 1.78
Price To Book 8.89
Market Cap 179318680
Shares 106,105,728
Volume 207,899
Short Ratio
Av. Daily Volume 455,082

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA approval announced October 15, 2018.
YUTIQ
Non-infectious uveitis
sNDA filing due 2019 for 6-month formulation.
Yutiq
Non-infectious uveitis

Latest News

  1. Edited Transcript of EYPT earnings conference call or presentation 8-May-19 12:30pm GMT
  2. EyePoint Pharmaceuticals to Present at Upcoming Investor Conferences
  3. EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Misses Revenue Estimates
  4. EyePoint Pharmaceuticals: 1Q Earnings Snapshot
  5. EyePoint Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress
  6. Will EyePoint Pharmaceuticals (EYPT) Report Negative Earnings Next Week? What You Should Know
  7. EyePoint Pharmaceuticals Presents Positive YUTIQ™ 36-month Follow-up Phase 3 Data at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
  8. EyePoint Pharmaceuticals Announces First Quarter 2019 Financial Results Release Date and Conference Call Information
  9. EyePoint Pharmaceuticals to Present at Upcoming Medical Conferences
  10. Here's Why EyePoint Pharmaceuticals Saw Its Share Price Drop Today
  11. EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  12. EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
  13. Edited Transcript of EYPT earnings conference call or presentation 14-Mar-19 12:30pm GMT
  14. EYEPOINT PHARMACEUTICALS INC (EYPT) Q2 2019 Earnings Conference Call Transcript
  15. EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates
  16. EyePoint Pharmaceuticals: Fiscal 2Q Earnings Snapshot
  17. EyePoint Pharmaceuticals Reports Fiscal Period Ended December 31, 2018 Financial Results and Highlights Recent Clinical and Operational Developments
  18. The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie
  19. EyePoint Pharmaceuticals Announces U.S. Commercial Launch of DEXYCUTM (dexamethasone intraocular suspension) 9%